These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 32446166)

  • 1. Clinical validation of the Cobas 4800 HPV assay using cervical samples in SurePath medium under the VALGENT4 framework.
    Ejegod DM; Hansen M; Christiansen IK; Pedersen H; Quint W; Xu L; Arbyn M; Bonde J
    J Clin Virol; 2020 Jul; 128():104336. PubMed ID: 32446166
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical and Analytical Performance of the BD Onclarity HPV Assay with SurePath Screening Samples from the Danish Cervical Screening Program Using the VALGENT Framework.
    Bonde JH; Pedersen H; Quint W; Xu L; Arbyn M; Ejegod DM
    J Clin Microbiol; 2020 Jan; 58(2):. PubMed ID: 31723012
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical performance of the HPV-Risk assay on cervical samples in SurePath medium using the VALGENT-4 panel.
    Heideman DAM; Xu L; Hesselink AT; Doorn S; Ejegod DM; Pedersen H; Quint WGV; Bonde J; Arbyn M
    J Clin Virol; 2019 Dec; 121():104201. PubMed ID: 31629967
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Valgent4 protocol: Robust analytical and clinical validation of 11 HPV assays with genotyping on cervical samples collected in SurePath medium.
    Bonde J; Ejegod DM; Cuschieri K; Dillner J; Heideman DAM; Quint W; Pavon Ribas MA; Padalko E; Christiansen IK; Xu L; Arbyn M
    J Clin Virol; 2018 Nov; 108():64-71. PubMed ID: 30253376
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical and analytical performance of the CLART HPV 4S assay with SurePath screening samples from the Danish cervical cancer screening program using the VALGENT framework.
    Ejegod DM; Pedersen H; Quint W; Xu L; Arbyn M; Bonde JH
    J Virol Methods; 2021 Jun; 292():114118. PubMed ID: 33766660
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical and Analytical Evaluation of the Anyplex II HPV HR Detection Assay within the VALGENT-3 Framework.
    Oštrbenk A; Xu L; Arbyn M; Poljak M
    J Clin Microbiol; 2018 Nov; 56(11):. PubMed ID: 30209184
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Validation of cobas 4800 HPV assay in SurePath Papanicolaou specimens for cervical cancer screening.
    Guo M; Shlyakhova N; Khanna A; Tinnirello AA; Schmeler KM; Hwang J; Sturgis EM; Stewart J
    J Am Soc Cytopathol; 2021; 10(4):399-405. PubMed ID: 33967024
    [TBL] [Abstract][Full Text] [Related]  

  • 8. VALGENT: A protocol for clinical validation of human papillomavirus assays.
    Arbyn M; Depuydt C; Benoy I; Bogers J; Cuschieri K; Schmitt M; Pawlita M; Geraets D; Heard I; Gheit T; Tommasino M; Poljak M; Bonde J; Quint W
    J Clin Virol; 2016 Mar; 76 Suppl 1():S14-S21. PubMed ID: 26522865
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessment of the Roche Linear Array HPV Genotyping Test within the VALGENT framework.
    Xu L; Oštrbenk A; Poljak M; Arbyn M
    J Clin Virol; 2018 Jan; 98():37-42. PubMed ID: 29241150
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical validation of full genotyping CLART® HPV4S assay on SurePath and ThinPrep collected screening samples according to the international guidelines for human papillomavirus test requirements for cervical screening.
    Ejegod DM; Lagheden C; Bhatia R; Pedersen H; Boada EA; Sundström K; Cortés J; Josë FXB; Cuschieri K; Dillner J; Bonde J
    BMC Cancer; 2020 May; 20(1):396. PubMed ID: 32375689
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of the Clinical Performance of the HPV-Risk Assay Using the VALGENT-3 Panel.
    Polman NJ; Oštrbenk A; Xu L; Snijders PJF; Meijer CJLM; Poljak M; Heideman DAM; Arbyn M
    J Clin Microbiol; 2017 Dec; 55(12):3544-3551. PubMed ID: 29021152
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical Performance of the Full Genotyping Agena MassARRAY HPV Assay Using SurePath Screening Samples within the VALGENT4 Framework.
    Pedersen H; Ejegod DM; Quint W; Xu L; Arbyn M; Bonde J
    J Mol Diagn; 2022 Apr; 24(4):365-373. PubMed ID: 35123039
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Performance of a Cartridge-Based Assay for Detection of Clinically Significant Human Papillomavirus (HPV) Infection: Lessons from VALGENT (Validation of HPV Genotyping Tests).
    Cuschieri K; Geraets D; Cuzick J; Cadman L; Moore C; Vanden Broeck D; Padalko E; Quint W; Arbyn M
    J Clin Microbiol; 2016 Sep; 54(9):2337-42. PubMed ID: 27385707
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical and Analytical Evaluation of the Alinity m HR HPV Assay within the VALGENT-3 Framework.
    Dhillon SK; Oštrbenk Valenčak A; Xu L; Poljak M; Arbyn M
    J Clin Microbiol; 2021 May; 59(6):. PubMed ID: 33731413
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical evaluation of a GP5+/6+-based luminex assay having full high-risk human papillomavirus genotyping capability and an internal control.
    Geraets DT; Cuschieri K; de Koning MN; van Doorn LJ; Snijders PJ; Meijer CJ; Quint WG; Arbyn M
    J Clin Microbiol; 2014 Nov; 52(11):3996-4002. PubMed ID: 25210073
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical and analytical performance of the PapilloCheck HPV-Screening assay using the VALGENT framework.
    Heard I; Cuschieri K; Geraets DT; Quint W; Arbyn M
    J Clin Virol; 2016 Aug; 81():6-11. PubMed ID: 27262102
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical validation of the Roche cobas HPV test on the Roche cobas 5800 system for the purpose of cervical screening.
    Mehta N; Keung MHT; Pineda E; Lynn E; Fetene D; Lee A; Hougardy N; Heinrichs A; Chan HTM; Arbyn M; Saville M; Hawkes D
    Microbiol Spectr; 2024 Oct; 12(10):e0149324. PubMed ID: 39258912
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 2020 list of human papillomavirus assays suitable for primary cervical cancer screening.
    Arbyn M; Simon M; Peeters E; Xu L; Meijer CJLM; Berkhof J; Cuschieri K; Bonde J; Ostrbenk Vanlencak A; Zhao FH; Rezhake R; Gultekin M; Dillner J; de Sanjosé S; Canfell K; Hillemanns P; Almonte M; Wentzensen N; Poljak M
    Clin Microbiol Infect; 2021 Aug; 27(8):1083-1095. PubMed ID: 33975008
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical Evaluation of INNO-LiPA HPV Genotyping
    Xu L; Padalko E; Oštrbenk A; Poljak M; Arbyn M
    Int J Mol Sci; 2018 Sep; 19(9):. PubMed ID: 30208597
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of the analytical and clinical performance of five tests for the detection of human papillomavirus genital infection.
    Del Pino M; Alonso I; Rodriguez-Trujillo A; Bernal S; Geraets D; Guimerà N; Torne A; Ordi J
    J Virol Methods; 2017 Oct; 248():238-243. PubMed ID: 28739302
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.